VERONA PHARMA PLC - Notice of Results
PR Newswire
London, September 22
 Verona Pharma plc

 ("Verona Pharma" or the "Company")

 Notice of Results

London, UK, 23September 2013 - Verona Pharma plc (AIM:VRP), the drug
development company focused on "first-in-class" medicines to treat respiratory
diseases, will announce its interim results for the six months ended 30 June
2013 on Monday 30 September 2013.

 -Ends-

For further information please contact:

Verona Pharma plc Tel: 020 7863 3300

Clive Page, Chairman

Jan-Anders Karlsson, CEO

Richard Bungay, CFO

WH Ireland Limited Tel: 020 7220 1666

Chris Fielding

Nick Field

FTI Consulting Tel: 020 7831 3113

Julia Phillips

Simon Conway

Notes to Editors

About Verona Pharma plc

Verona Pharma is developing first-in-class drugs to treat respiratory disease,
such as COPD, asthma and chronic, severe cough. The Company has three drug
programmes, two of which are in Phase II. The lead programme, RPL554, is an
innovative dual phosphodiesterase (PDE) 3 and 4 inhibitor with both
bronchodilator and anti-inflammatory properties. VRP700 is an innovative
product for suppressing chronic, severe cough in patients with underlying lung
disease. In its third programme, Verona Pharma is investigating novel
anti-inflammatory molecules, called NAIPs, for a wide range of respiratory and
inflammatory diseases.

About RPL554 for the treatment of COPD and Asthma

Verona's lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor
being developed as a novel treatment for chronic obstructive airways disease
such as COPD and asthma with bronchodilator and anti-inflammatory effects. Both
effects are essential to improve symptoms in patients with COPD or asthma.
RPL554 is currently in phase II for both diseases.

COPD is a chronic lung disease with significant unmet need for which current
treatment is far from optimal, as it often has unwanted side-effects and/or
limited effectiveness. COPD is most commonly characterised by fixed airflow
obstruction and chronic airways inflammation resulting from exposure to
irritants like tobacco smoke. Asthma, which remains one of the most common
chronic diseases in the world, is characterised by recurrent breathing problems
and symptoms such as breathlessness, wheezing, chest tightness, and coughing.
The market for COPD and asthma drugs is currently estimated to be GBP20 billion
[source: visiongain].

About VRP700 for the treatment of Cough

VRP700 is Verona Pharma's lead drug compound for the treatment of cough, having
a novel mechanism of action involving the suppression of cough initiating
signals originating from cough sensory nerve endings located in the lungs. A
clinical trial completed at the University of Florence, Italy in September 2011
clearly demonstrated significant anti-tussive effects with nebulised VRP700 in
hospitalized patients with chronic severe cough.

Cough can be a very debilitating comorbidity reported by patients, especially
those with respiratory conditions such as asthma, COPD, lung cancer,
interstitial lung disease, fibrosis or lung infections. It is a neglected
symptom which is often self-medicated. Consumer spending on OTC medications,
including those for cough, grew by 10% over 2005-10, to reach GBP532 million in
UK [source: Mintel]. However, there is very little clinical evidence for such
OTC cough medications being really effective and it is widely recognised by the
medical community that there is a large need for more effective drugs to
control and prevent pathologically induced coughing.
Verona Pharma

Investor Information
